CIDP, Centre International de Développement Pharmaceutique, a Mauritius-based private and independent Contract Research Organisation (CRO), is proud to announce the inauguration of its new Asia subsidiary in Singapore. This marks the Group’s first foray into the Asia-Pacific region, and is its fourth subsidiary after the ones located in Romania, India, and Brazil.
“We felt the need to expand internationally in order to broaden our services and diversify our skills”, said Jean-Louis Roule, French CEO of CIDP. “This fuelled our decision to set up a new subsidiary in Asia, a region we are keen to serve due to its increasing economic importance. Singapore was a logical choice for our Asia office because of its excellent infrastructure, transparency of requirements and regulations, and convenient access to Asian markets. We are confident that this new venture will bring CIDP to greater heights.”
CIDP is a pioneer international group that specialises in research and development activities for pharmaceutical, medical device, nutrition, and cosmetic industries. With more than 15 years of experience, CIDP is a leading company in the field offering extensive scientific expertise in the dermo-cosmetics sector. The CIDP group comprises a strong team of highly qualified and experienced professionals, such as doctors, pharmacists, clinical research/trial assistants and managers, biostatisticians, and data managers. CIPD’s scientific know-how covers various aspects of drug discovery, and services offered include the evaluation of ingredients, raw materials, as well as drugs or cosmetics products.
CIDP’s Singapore subsidiary was officially unveiled in a ceremony held on 27 January. The opening was officiated by Claire Blazy-Jauzac, Group Managing Director of CIDP, and was attended by around 50 guests, including clients, business partners, embassy, and association representatives, etc. Located in Biopolis, an international research and development hub for biomedical sciences, the fully operational centre is equipped with the latest technologies, and its investiture will enable CIDP to enhance its expertise in dermatology and cosmetics activities, and facilitate the development of new partnerships in R&D across the region.
Matsuoka Nobuaki, Vice-President of the Society of Cosmetics Scientists Singapore and Principle Scientist at Procter & Gamble Singapore commented, “It’s a good thing to have more CROs in Singapore catering to local and regional companies that seek professional services for their development projects. I think CIDP’s presence in Singapore will help the industry, both for large laboratories that will benefit from the CIDP’s expertise in dermatology and cosmetics for their clinical research projects, and for start-ups who fully outsource their in vitro or in vivo testing needs. I would like to congratulate CIDP on their expansion and I Iook forward to more fruitful collaborations and new developments within the industry from Singapore and beyond.”
About Centre International de Développement Pharmaceutique (CIDP)
Based in Mautitius, CIDP, Centre International de Développement Pharmaceutique is a private and independent Contract Research Organisation (CRO) that conducts high performing research and clinical activities for pharmaceutical, medical device, nutrition and cosmetic industries. The group serves clients both as a service provider upstream through Research and Preclinical activities, and downstream through Regulatory Affairs, Biostatistics & Data Management, and Clinical Research. The geographical locations of CIDP’s centres enable access to a wide panel of patients. This allows the group to undertake multi-centric trials with a rapid recruitment process in a secured and adapted environment. Recognised for its expertise, CIDP works with the leaders of the cosmetics and pharmaceutical industry.
CIDP forms part of the GML group. GML is ranked among the 16 most dynamic and fast growing companies in Africa, according to the World Economic Forum in 2014. Ranked number 1 in the TOP 100 Mauritian companies and number 3 in the Indian Ocean, GML invests in Life sciences through its subsidiary: GML Life. Its ambition is to become the essential starting point in this growing sector.